ANTX files 8-K, furnishes Q3 2025 results press release

AN2 Therapeutics (ANTX) filed an 8-K to announce it furnished a press release with financial results for the third quarter ended September 30, 2025.

Rhea-AI Filing Summary

AN2 Therapeutics (ANTX) filed an 8-K to announce it furnished a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and, as stated, the information under Item 2.02 is being furnished, not filed.

The company lists its principal executive offices at 1300 El Camino Real, Suite 100, Menlo Park, CA 94025, and provides a former address at 1800 El Camino Real, Suite D, Menlo Park, CA 94027.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ANTX announce in this 8-K?

The company furnished a press release with its Q3 2025 financial results under Item 2.02.

Which period do the results cover for ANTX?

They cover the third quarter ended September 30, 2025.

Is the ANTX Q3 2025 press release considered filed?

No. The information under Item 2.02 is furnished, not filed.

Where can I find the ANTX press release?

It is attached as Exhibit 99.1 to the 8-K.

What is ANTX’s current listed address?

The principal executive offices are at 1300 El Camino Real, Suite 100, Menlo Park, CA 94025.

Does the filing show a former ANTX address?

Yes, it lists a former address at 1800 El Camino Real, Suite D, Menlo Park, CA 94027.

What is ANTX’s trading symbol and exchange?

The common stock trades as ANTX on The Nasdaq Global Select Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 04:19 PM EST Learn about SEC filing dates

false00018804380001880438dei:FormerAddressMember2025-11-122025-11-1200018804382025-11-122025-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

AN2 Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41331	82-0606654
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1300 El Camino Real, Suite 100
Menlo Park, California				94025
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 331-9090

AN2 Therapeutics, Inc.

1800 El Camino Real, Suite D

Menlo Park, California 94027

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		ANTX		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Press Release of AN2 Therapeutics Inc. dated November 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AN2 Therapeutics, Inc.
Date:	November 12, 2025	By:	/s/ Eric Easom
			Eric Easom Chief Executive Officer and Director (Principal Executive Officer)